Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com

Rhea-AI Summary

Aprea Therapeutics, Inc. (Nasdaq: APRE) has launched p53reactivation.com to enhance disease awareness regarding p53 mutations in cancer. This initiative aims to educate healthcare professionals on how these mutations are linked to poor treatment outcomes. With approximately half of all cancers featuring p53 mutations, the site seeks to promote understanding of diagnostic tests and potential targeted therapies, marking a significant step in addressing this unmet medical need.

Positive

• Launch of p53reactivation.com to raise awareness about p53 mutations in cancer.
• Educational initiative aims to inform healthcare professionals about diagnostic tests and reactivation therapies.

Negative

• None.

BOSTON, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, today announced the launch of p53reactivation.com. The new website contributes to Aprea’s disease awareness initiative to educate healthcare professionals on the importance of p53 mutations in cancer and reactivation of mutant p53 as a potential therapeutic option for the treatment of cancer.

“Mutations in p53 are present in approximately half of all cancers and are often associated with poor treatment outcomes and resistance to traditional anti-cancer therapies,” said Eyal Attar, M.D., Senior Vice President and Chief Medical Officer of Aprea Therapeutics. “Knowledge of the poor prognoses that accompany p53 mutations, the availability of diagnostic tests for their identification, and awareness of mutant p53 reactivation as a potential targeted therapeutic option, may collectively advance detection and treatment for cancer patients with this important and significant unmet medical need.”

Corporate Contacts:

Scott M. Coiante
Sr. Vice President and Chief Financial Officer
617-463-9385

Gregory A. Korbel
Vice President of Business Development
617-463-9385

Source: Aprea Therapeutics, Inc.

FAQ

What is the purpose of p53reactivation.com launched by Aprea Therapeutics?

The website aims to educate healthcare professionals about p53 mutations in cancer and their role in treatment resistance.

How common are p53 mutations in cancer according to Aprea Therapeutics?

Approximately half of all cancers feature p53 mutations, which are often linked to poor treatment outcomes.

When was the p53reactivation.com website launched?

The website was launched on October 14, 2020.

What kind of therapeutic options does Aprea Therapeutics promote for p53 mutations?

Aprea Therapeutics promotes mutant p53 reactivation as a potential targeted therapeutic option for cancer treatment.